JP2025508016A - Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 - Google Patents

Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 Download PDF

Info

Publication number
JP2025508016A
JP2025508016A JP2024552797A JP2024552797A JP2025508016A JP 2025508016 A JP2025508016 A JP 2025508016A JP 2024552797 A JP2024552797 A JP 2024552797A JP 2024552797 A JP2024552797 A JP 2024552797A JP 2025508016 A JP2025508016 A JP 2025508016A
Authority
JP
Japan
Prior art keywords
compound
pharma
acceptable salt
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508016A5 (enExample
Inventor
ジョン シムズ，マーティン
アルバート ウォード，ジョージ
スミス，トモコ
ボルタクール，ゴータム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2025508016A publication Critical patent/JP2025508016A/ja
Publication of JP2025508016A5 publication Critical patent/JP2025508016A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024552797A 2022-03-04 2023-03-03 Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 Pending JP2025508016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316680P 2022-03-04 2022-03-04
US63/316,680 2022-03-04
PCT/US2023/063669 WO2023168394A1 (en) 2022-03-04 2023-03-03 Methods of treating cancer with iap antagonist compounds and combination therapies

Publications (2)

Publication Number Publication Date
JP2025508016A true JP2025508016A (ja) 2025-03-21
JP2025508016A5 JP2025508016A5 (enExample) 2026-03-12

Family

ID=85792184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552797A Pending JP2025508016A (ja) 2022-03-04 2023-03-03 Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法

Country Status (7)

Country Link
US (1) US20250186451A1 (enExample)
EP (1) EP4486352A1 (enExample)
JP (1) JP2025508016A (enExample)
KR (1) KR20240156407A (enExample)
AU (1) AU2023229084A1 (enExample)
TW (1) TW202345849A (enExample)
WO (1) WO2023168394A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
CN120379671A (zh) * 2022-10-18 2025-07-25 辉瑞公司 用于治疗癌症的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Also Published As

Publication number Publication date
KR20240156407A (ko) 2024-10-29
US20250186451A1 (en) 2025-06-12
AU2023229084A1 (en) 2024-10-17
TW202345849A (zh) 2023-12-01
EP4486352A1 (en) 2025-01-08
WO2023168394A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7206314B2 (ja) Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置
JP6880101B2 (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
KR102449712B1 (ko) 아미노티아졸 화합물 및 이의 용도
JP6522807B2 (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN114901277A (zh) 用于egfr降解的异吲哚啉酮和吲唑化合物
BR102018007822A2 (pt) composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN110114071A (zh) 含有取代的吡啶酮的三环化合物以及使用其的方法
CN104640858A (zh) 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法
KR20180005178A (ko) 치환된 퀴나졸린 화합물 및 이의 사용방법
CN114008024A (zh) 具有铁死亡诱导活性的化合物以及使用其的方法
JP2025508016A (ja) Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法
CN115381832A (zh) 癌症的治疗
CN106573927A (zh) 氧杂环庚烷‑2‑基‑吡唑‑4‑基‑杂环基‑甲酰胺化合物和使用方法
US20250122191A1 (en) Compounds as bcl-2 inhibitors
WO2022268065A1 (en) Compounds as erk inhibitors
US20220227716A1 (en) Benzimidazole and hydrogenated carbazole derivatives as gpx4 inhibitors
HK40020967B (en) Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
HK40083903A (en) Treatment of cancer
HK40095032A (zh) 一种药物组合物及其在治疗癌症中的用途
HK40095032B (zh) 一种药物组合物及其在治疗癌症中的用途
HK40112782A (zh) 用於egfr降解的异吲哚啉酮和吲唑化合物
HK40122816A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK40049323A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK40067758A (en) Compounds with ferroptosis inducing activity and methods of their use
HK40001545A (en) Treatment of cancer

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260303